WallStSmart

Fresenius Medical Care Corporation (FMS)vsNewGenIvf Group Limited Class A Ordinary Shares (NIVF)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 410935% more annual revenue ($19.43B vs $4.73M). NIVF leads profitability with a 209.0% profit margin vs 4.8%. FMS earns a higher WallStSmart Score of 58/100 (C).

FMS

Buy

58

out of 100

Grade: C

Growth: 4.7Profit: 5.0Value: 9.3Quality: 6.0
Piotroski: 6/9Altman Z: 1.96

NIVF

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.0Quality: 9.0
Piotroski: 4/9Altman Z: 4.07
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FMSUndervalued (+68.6%)

Margin of Safety

+68.6%

Fair Value

$76.58

Current Price

$22.35

$54.23 discount

UndervaluedFair: $76.58Overvalued

Intrinsic value data unavailable for NIVF.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
11.7x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

PEG RatioValuation
0.738/10

Growing faster than its price suggests

NIVF5 strengths · Avg: 9.8/10
Price/BookValuation
0.0x10/10

Reasonable price relative to book value

Return on EquityProfitability
79.4%10/10

Every $100 of equity generates 79 in profit

Profit MarginProfitability
209.0%10/10

Keeps 209 of every $100 in revenue as profit

Altman Z-ScoreHealth
4.0710/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Areas to Watch

FMS4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Return on EquityProfitability
7.5%3/10

ROE of 7.5% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

NIVF3 concerns · Avg: 2.7/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.43M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
-349.1%1/10

Operating margin of -349.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bull Case : NIVF

The strongest argument for NIVF centers on Price/Book, Return on Equity, Profit Margin. Profitability is solid with margins at 209.0% and operating margin at -349.1%. Revenue growth of 11.9% demonstrates continued momentum.

Bear Case : FMS

The primary concerns for FMS are Revenue Growth, Altman Z-Score, Return on Equity. Thin 4.8% margins leave little buffer for downturns.

Bear Case : NIVF

The primary concerns for NIVF are EPS Growth, Market Cap, Operating Margin.

Key Dynamics to Monitor

FMS profiles as a value stock while NIVF is a mature play — different risk/reward profiles.

FMS carries more volatility with a beta of 0.83 — expect wider price swings.

NIVF is growing revenue faster at 11.9% — sustainability is the question.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

FMS scores higher overall (58/100 vs 57/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

NewGenIvf Group Limited Class A Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

NewGenIvf Group Limited (NIVF) is a pioneering organization in the reproductive health industry, specializing in innovative fertility solutions, including advanced in vitro fertilization (IVF) services. The company is dedicated to enhancing success rates in assisted reproductive technologies and is strategically positioned to capitalize on the growing global demand for fertility treatments, supported by a robust network of clinics and strategic partnerships. As the fertility services market continues to expand, NIVF is well-equipped for substantial growth, with a mission to assist individuals and couples in their journey to parenthood through forward-thinking healthcare solutions.

Want to dig deeper into these stocks?